High Risk HPV Treatment Tracker
Last Updated October 9th, 2017
I still care.
This website is to help those who have High Risk HPV track progress on therapeutic vaccines and natural treatment clinical trials and studies
VGX-3100
Completed Phase II and about to start Phase III. Waiting for FDA to lift hold on delivery device.
VGX-3100 by Inovio is “an investigational DNA immunotherapy candidate designed to treat precancers and cancers caused by human papillomavirus (HPV).” This the farthest any therapeutic vaccine clinical trial has progressed by concluding Phase II with promising results and are hoping to start Phase III as soon as the FDA lifts a clinical hold on their delivery device. Inovio does not see the hold as being a major problem. Their goal is to file to sell in the market by 2020.
UPDATE (10/08/2017): Back in June, the FDA lifted the hold on their delivery device and Inovio is now recruiting for Phase III of their clinical trials. This is great news as Phase III means larger chance of reaching market which could happen in the next 3-4 years.
AHCC - Natural Treatment
Completed Phase I and currently underway with Phase II.
AHCC is a natural supplement mushroom extract from Japan. This is based on a real study currently underway at the University of Texas by Dr. Judith A. Smith. She studied the effects of AHCC on patients with high risk HPV infections and found that it had a huge impact in eradicating the infection. Patients took 3 grams of AHCC every morning on an empty stomach for 6 months. AHCC is an immune booster which helps the system fight against the HPV infection. The complete results are not in yet but it is promising to see and there have been a lot of anecdotes on the internet. This is something that can be tried today since it’s available on the market.
Phone: Judith A Smith 713-500-6408
Email: Judith.Ann.Smith@uth.tmc.edu
ABI-1968
Currently underway with Phase IB
Antiva's goal is "to make treating this precancerous condition as routine as treating a yeast infection." ABI-1968 is a topical cream designed to have potent anti-viral activity. It's based on a molecule invented by a professor at University of California, San Diego, Karl Hostetler. Antiva has generated a lot of funding and is making this product it's primary goal. Phase II probably won't start until 2019 which means that there is still a while before this treatment is available in the market.
Axalimogene Filolisbac
Just started Phase III
Axalimogene Filolisbac is an immunotherapy candidate that targets "high risk locally advanced cervical cancer." It's not clear if this can be applied to patients that only have the HPV infection/pre-cancerous cells. The study has started Phase III and has a FastTrack status from the FDA.
Ademedus HPV
Will start Phase I this year
The creator of the vaccine, Gardisil, Professor Ian Frazer is working on a therapeautic vaccine targetting HPV in it's early stages.